Harrow Closes Acquisition of Tyrvaya, a Dry Eye Disease Treatment From Viatris Inc.
Harrow (HROW) completed its acquisition of Tyrvaya, a dry eye treatment, from Viatris. Harrow paid $30M upfront, with up to $70M in milestones. Tyrvaya is FDA-approved and complements Harrow's existing dry eye therapy, Vevye. Harrow expects Tyrvaya to generate over $30M in 2027 revenue.
How this was made
The 30-second read
Why it matters
The deal adds a new revenue stream and expands Harrow's product suite, while Viatris retains a royalty stream in Japan.
Market read
First‑report acquisition of a niche eye‑care product; modest but material for Harrow, neutral for Viatris.
What to watch
Potential regulatory or reimbursement hurdles for the nasal spray in new markets could delay revenue
Background
Harrow, a Nasdaq‑listed ophthalmic solutions provider, completed its purchase of Tyrvaya from Viatris, adding the only FDA‑approved dry‑eye nasal spray to its portfolio.
Ticker impact
Harrow closed its acquisition of Tyrvaya, paying $30M cash with up to $70M milestones, adding a new FDA‑approved dry‑eye nasal spray to its portfolio.
likely upside as the market prices in added revenue and pipeline diversification
The acquisition adds a $30M+ revenue stream in 2027 and brings experienced staff, which should be viewed favorably by investors.
Viatris retained Japanese rights to Tyrvaya and will receive royalties on future sales there after selling the rest of the rights to Harrow.
likely neutral to slight pressure as the royalty stream is modest relative to overall sales
The royalty arrangement provides upside but does not materially change Viatris' broader earnings outlook.
Market effects
strengthens the ophthalmic/ocular‑surface therapeutic segment with a new delivery modality
U.S. dry‑eye market sees added competition; Japan market remains unchanged
limited to eye‑care niche, no broad market ripple
Counterpoint
The acquisition price may be high relative to Tyrvaya's modest sales, risking dilution of Harrow's balance sheet
Key entities
- CompanyHarrow
Nasdaq‑listed ophthalmic disease management firm (ticker HROW)
- CompanyViatris Inc.
Global healthcare company (ticker VTRS) selling Tyrvaya rights
